ZVRA
Zevra Therapeutics, Inc.
$12.77
+0.01 (+0.08%)
At close · Jul 17
Market Cap
$754.90M
Shares
59,115,084
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$106.47M
+350.9%
FY2025
Net Income
$83.23M
+178.9%
FY2025
Gross Margin
89.28%
-8.5pp
FY2023
Operating Margin
-59.12%
+309.4pp
FY2025
Diluted EPS
$1.35
+159.2%
FY2025
Operating Cash Flow
-$1.6M
+97.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $122.29M | $106.47M | $23.61M | $27.46M | $10.16M | $28.65M | $13.29M | $12.84M | $0 | — | — | $0 | $0 | $0 | |
| — | — | — | $2.95M | $222K | $2.06M | — | $10M | $0 | — | — | — | — | — | |
| — | — | — | $24.52M | $9.94M | $26.59M | — | $2.84M | $0 | — | — | — | — | — | |
| — | — | — | 89.28% | 97.82% | 92.81% | — | 22.11% | — | — | — | — | — | — | |
| $13.88M | $12.74M | $42.1M | $39.81M | $19.8M | $10.16M | $8.84M | $19.42M | $41.76M | $20.59M | $20.47M | $13.93M | $11.92M | $3.37M | |
| — | — | — | — | $15.34M | $8.7M | $7.92M | $10.82M | $12.51M | $12.77M | $14M | $8.88M | $4.53M | $1.35M | |
| $78.85M | $77.62M | $54.87M | $34.31M | $15.04M | — | — | — | — | — | — | — | — | — | |
| $2.56M | $3.86M | $6.24M | $772K | — | — | — | — | — | — | — | — | — | — | |
| — | $4.05M | $6.39M | $1.01M | $944K | $257K | $273K | $304K | $324K | $336K | $175K | $84K | $75K | $68K | |
| $46.39M | — | — | — | — | — | — | — | $55.9M | $33.37M | $37.48M | $22.81M | $16.44M | $4.72M | |
| $92.73M | $90.36M | $96.96M | $74.12M | $52.73M | $20.92M | $18.9M | $33.18M | $55.9M | — | — | — | — | — | |
| -$5.44M | -$62.94M | -$87M | -$49.6M | -$42.57M | $7.73M | -$5.61M | -$20.34M | -$55.9M | -$33.37M | -$37.48M | -$22.81M | -$16.44M | -$4.72M | |
| — | -59.12% | -368.47% | -180.63% | -418.91% | 26.98% | -42.21% | -158.4% | — | — | — | — | — | — | |
| — | -$58.89M | -$80.61M | -$48.6M | -$41.62M | $7.99M | -$5.34M | -$20.03M | -$55.58M | -$33.03M | -$37.31M | -$22.73M | -$16.37M | -$4.65M | |
| $7.72M | $7.98M | $7.35M | $1.5M | $335K | $226K | $4.79M | $4.86M | $5.47M | $5.78M | $5.51M | $2.67M | $1.61M | $157K | |
| $138.83M | $149.62M | -$3.14M | $3.56M | $15.76M | -$16.25M | -$7.19M | -$4.21M | -$689K | -$10.06M | $20.95M | -$31.82M | -$8.03M | -$528K | |
| $133.4M | $86.68M | -$90.14M | -$46.05M | -$26.81M | -$8.52M | -$12.79M | -$24.54M | -$56.59M | -$43.43M | -$16.53M | -$54.64M | -$24.48M | -$5.25M | |
| $9.18M | $3.45M | $15.37M | $0 | -$33K | $34K | -$34K | -$22K | -$126K | -$43K | -$15K | $26K | -$22K | -$20K | |
| $124.22M | $83.23M | -$105.51M | -$46.05M | -$26.77M | -$8.56M | -$12.76M | -$24.52M | -$56.47M | -$43.39M | -$16.52M | -$54.66M | -$24.46M | -$5.23M | |
| — | 78.17% | -446.85% | -167.69% | -263.48% | -29.86% | -96.03% | -191% | — | — | — | — | — | — | |
| $117M | $77.59M | -$105.51M | -$46.05M | -$26.77M | -$62.9M | -$12.76M | — | — | — | — | — | — | — | |
| $122.5M | $81.83M | -$104.84M | -$46.21M | -$26.66M | -$62.9M | — | — | — | — | — | — | — | — | |
| USD/shares | — | $1.40 | -$2.28 | -$1.30 | -$0.78 | -$2.11 | -$3.21 | — | — | — | — | — | — | — |
| USD/shares | — | $1.35 | -$2.28 | — | — | -$2.11 | -$3.21 | — | — | — | — | — | — | — |
| shares | — | 55.31M | 46.25M | 35.45M | 34.49M | 29.77M | 3.98M | 1.85M | 1.12M | 915.81K | 912.32K | 460.54K | 148.82K | 148.82K |
| shares | — | 57.26M | 46.25M | — | — | 29.77M | 3.98M | 1.85M | 1.12M | 915.81K | 912.32K | 460.54K | 148.82K | 148.82K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2020–FY2024: $10.98M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.75×
EV/EBIT
—
Biotechnology median 26.36×
P/E (TTM)
6.35×
Biotechnology median 7.37×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Reportable Segment | $106,470,000 | $23,612,000 |
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| MIPLYFFA | $87,400,000 | $10,100,000 | — | — | — |
| Olpruva | $800,000 | $100,000 | — | — | — |
| Consulting Services | — | — | $100,000 | $100,000 | $1,700,000 |
Key facts
CIK
1434647
CUSIP
488445206
13F (30d)
11 filings
11 filers
Visit website
Investor relations